Johnson & Johnson Jumps on Pharma Strength
Johnson & Johnson (NYSE: JNJ) has been a behemoth in the U.S. healthcare space for decades. Yet as a mature company, J&J faces the inevitable challenge of finding ways to keep its growth rates up even as its business gets ever larger. Results from recent quarters had shown signs of potentially slowing increases in sales and profits, and that raised some worries among longtime investors that Johnson & Johnson might have hit peak growth in its core business.
Coming into Tuesday's third-quarter financial report, Johnson & Johnson shareholders wanted reassurances that aggressive moves like the acquisition of Actelion would pay off with better fundamental performance. J&J's report strongly suggested that its long-term strategy is working well, and the company seems more optimistic than ever that its combination of organic growth opportunities and smart acquisitions can help power it forward in the years to come.
Image source: Johnson & Johnson.
Source: Fool.com
Johnson & Johnson Stock
The stock is one of the favorites of our community with 41 Buy predictions and 1 Sell predictions.
With a target price of 192 € there is a positive potential of 31.47% for Johnson & Johnson compared to the current price of 146.04 €.
